Ronald L. Gibson, Jr., M.D., Ph.D.
CURRICULUM VITAE
Ronald L. Gibson, Jr., M.D., Ph.D.
Education
Undergraduate:
1972-75
Graduate:
1976-82
University of Washington, Seattle, Washington - Major field
of Biology, B.S.
Washington University Schools of Medicine and Arts &
Sciences, St. Louis, Missouri - M.D. and Ph.D.
Doctoral Thesis: The role of oligosaccharide chains in the
maturation and physical properties of the G protein of
vesicular stomatitis virus
Postgraduate Training
Internship:
1982-83
Residency:
1983-85
1985
Fellowship:
1985-88
Pediatrics, University of Washington School of Medicine,
Seattle, Washington
Pediatrics, University of Washington School of Medicine,
Seattle, Washington
Assistant Chief Pediatric Resident, University of
Washington School of Medicine, Seattle, Washington
Pediatric Pulmonology, Department of Pediatrics,
University of Washington School of Medicine, Seattle,
Washington
Faculty Positions Held
1988-1994
Assistant Professor, Department of Pediatrics, University of Washington School
of Medicine, Seattle, Washington
1991-1997
Research Affiliate, Child Development and Mental Retardation Center, University
of Washington, Seattle, Washington
1994-2003
Associate Professor, Department of Pediatrics, University of Washington School
of Medicine, Seattle, Washington
2003Professor, Department of Pediatrics, University of Washington School of
Medicine, Seattle, Washington
Hospital Positions Held
1988Attending Physician, Children's Hospital & Regional Medical Center, Seattle,
Washington
1988Consultant, University of Washington Medical Center, Seattle, Washington
1994-99
Consultant, Swedish Hospital & Medical Center Special Care Nursery, Seattle,
Washington
Honors and Awards
1975
B.S. summa cum laude in Biology
1975
Phi Beta Kappa, University of Washington, Seattle, Washington
1976-82
Medical Scientist Training Grant from the National Institutes of Health,
Washington University School of Medicine, St. Louis, Missouri
1
Ronald L. Gibson, Jr., M.D., Ph.D.
1977
1982
1982
1991
1997
1997
1999
2000
2000
2001
2002
Richard S. Brookings Medical Prize, Washington University School of Medicine,
St. Louis, Missouri
Alexander Berg Prize in Microbiology, Washington University School of Medicine,
St. Louis, Missouri
Alpha Omega Alpha (AOA), Washington University School of Medicine, St. Louis,
Missouri
Outstanding Teacher Award, University of Washington School of Medicine,
Pediatric Residency Training Program
Stanley Stamm Role Model Award in Medicine (for conscientious teaching and
patient care), University of Washington School of Medicine, Pediatric Residency
Training Program
Society for Pediatric Research, Elected Member
Outstanding Teacher Award, University of Washington School of Medicine,
Pediatric Residency Training Program
Family Choice Award from the Parent Advisory Council at Children’s Hospital &
Regional Medical Center (CHRMC), Seattle, WA
Voted one of Seattle’s Top Doctors per Seattle Magazine
Nominee, Family Choice Award from Parent Advisory Council at CHRMC
Nominee, Family Choice Award from Parent Advisory Council at CHRMC
Grants/Research Awards
1985-1990
National Institutes of Health, Program Project (PI, W.A. Hodson):
Neonatal Pulmonary Circulation: Co-Investigator (R. Gibson)
1987
Research Training Fellowship, American Lung Association, 1987-88
$20,000
1987
Research Grant, American Lung Association: The Specificity and
$20,000
Bacterial Stimulus of Pulmonary Hypertension in Neonatal Sepsis
1988
Research Training Fellowship, American Lung Association, 1988-89
$20,000
1988-91
RJR Nabisco Research Scholar Award: Bacterial-Host Cell
$225,000
Interactions that Stimulate Proinflammatory Mediators in
Neonatal Group B Streptococcal Sepsis
1990-95
Maternal Child Health, Pediatric Pulmonary Center Training Grant
(P.I.: G. Redding, Co-I: R. Gibson)
1991-93
Research Grant, Washington Technology Center: The Role of
$200,000
Pulmonary Microvascular Endothelial Cell Response in Lung Disease
1991-94
Edward Livingston Trudeau Scholar Award, American Lung
$75,000
Association: Group B Streptococcus Endothelial Cell Interactions
1993-98
Co-PIs (B. Ramsey, R. Gibson)/Mentors of Leroy Matthews
Physician Scientist Award
$100,000
1995-2000
Maternal Child Health, Pediatric Pulmonary Center Training Grant
(P.I.: G. Redding, Co-I: R. Gibson)
1996-97
Cystic Fibrosis Foundation Grant
Gene Therapy in the Developing Airways of Mice
$70,000
1996-97
Cystic Fibrosis-Research Development Program Pilot Grant
$50,000
1998Cystic Fibrosis Clinical Care Center Grant (PI, R. Gibson)
~$220,000/year
1998-2003
Cystic Fibrosis Foundation Therapeutics Development Center
$900,000
(Co-PIs R. Gibson/Moira Aitken)
1999Director of the Clinical Core, CFF- Research Development Program
2000-2005
Maternal Child Health, Pediatric Pulmonary Center Training Grant
2
Ronald L. Gibson, Jr., M.D., Ph.D.
1999-2002
2000-2004
2003-2008
2003-
(P.I.: G. Redding, Co-I: R. Gibson)
Food and Drug Administration Orphan Product Development Grant:
$400,000
TOBI in Young Children with Cystic Fibrosis (Co-PI, R. Gibson)
National Institutes of Health: Inhaled Tobramycin in Young Cystic
$1,500,000
Fibrosis Patients (#RO1 DK57755-01, PI-B. Ramsey, Co-PI R. Gibson)
Cystic Fibrosis Foundation Therapeutics Development Center
$500,000
(Co-PIs R. Gibson/Moira Aitken)
Cystic Fibrosis Foundation Therapeutics: Standard vs. Biofilm
$442,000
Susceptibility Testing in CF (PI: J. Burns, Co-I: R. Gibson)
Board Certification
1982
National Board of Medical Examiners
1988Board Certified in Pediatrics (#36845)
1992-1999
Board Certified in Pediatric Pulmonology (#303)
2000-2006
Re-certified in Pediatric Pulmonology (PRCP-MS)
Licensure to Practice
1983Washington (# MD00021155)
Professional Organizations
National:
1986-88
American Academy of Pediatrics
1986American Thoracic Society
1992Pediatric Pulmonary Training Directors Association
1994-1998
American Society for Microbiology
1997Society for Pediatric Research
Local:
198919901990-
Washington Thoracic Society
Western Society for Pediatric Research
Washington Chapter, American Academy of Pediatrics
Teaching Responsibilities
Medical Students- Interact with 2-3 medical students each week of inpatient service with daily
case-based teaching in subspecialty rounds, or in weekly Chest/CF Clinic at
CHRMC
Residents- Interact closely with 6 residents on the Pulmonary Team and 1-2 additional residents
on the pulmonary elective for each week of subspecialty attending (16-20 weeks the past three
years). These interactions include cased-based teaching at the bedside and in outpatient
clinics, and 1-2 mini-lectures per week of attending.
Pediatric Pulmonology Trainees:
Timothy D. Murphy, M.D.
Margaret Rosenfeld, M.D.,M.P.H.
John P. Osborn, M.D.
Sonia K. Budhecha, M.D.
Toby S. Lewis, M.D., M.P.H.
Samuel M. Moskowitz, M.D.
3
Assistant Professor, University of Pittsburgh
Assistant Professor, Univ. of Washington
Clinical Assistant Professor, Univ. of Virginia
Assistant Professor, Univ. of Nevada, Reno
Instructor, University of Michigan
Acting Asst. Professor, Univ. of Washington
Ronald L. Gibson, Jr., M.D., Ph.D.
Jason Debley, M.D., M. P. H.
Martha McKinney, M.D. , M.P.H.
Lucas Hoffman, M.D., Ph.D.
Acting Asst. Professor, Univ. of Washington
Senior Fellow, University of Toronto
Editorial Responsibilities: no editorial boards
Special National and Regional Committees/Activities
1992Member, Pediatric Pulmonary Training Directors Association (PEPTDA)
1993
Member, Committee to Review the Uniformed Services Pediatric Seminar
Scientific Awards Competition for the Andrew Margileth Award
1995Coordinator/Moderator for Regional, Quarterly CF Clinical Conferences including
the University of Washington Adult Program, Spokane Affiliate Program, Tacoma
Affiliate Program, Anchorage Affiliate Program, and Invitees from the University of
Oregon and British Columbia
1997
Site Visit to Affiliate CF Program in Spokane, WA
1998Member, Steering Committee for the Cystic Fibrosis Therapeutic Development
Center Network
1998Member, Pediatric Planning Committee for the Cystic Fibrosis Foundation (CFF)
Therapeutic Development Center Network (TDN)
1998Member, PEPTDA Workforce and Recruitment Subcommittee
1998
Chairperson, Committee to develop Standard Operating Procedure for Spirometry
within the Cystic Fibrosis Foundation Therapeutic Development Network (TDN)
1998
Member, Committee to develop a Standard Operating Procedure for Nasal
Potential Difference Measurements within the CFF TDN
1997
Member, Data Safety Monitoring Committee for Intrabiotics-367 Multicenter
Phase I Study
1998
Speaker/Panelist at Roundtable Discussion on Guidelines for Assessing Affiliate
CF Centers at the 1998 North American CF Foundation Meeting
1998
Member, Committee to Review the Uniformed Services Pediatric Seminar
Scientific Awards Competition for the Andrew Margileth Award
1999
Site Visit to Affiliate CF Program in Anchorage, Alaska
1998
Visiting Professor, University of California, San Diego, including Grand Rounds at
Children’s Hospital, San Diego entitled “Cystic Fibrosis: Pathophysiology and
Update on Treatment”
1999
Invited Speaker for Post-Graduate Symposium on Aerosolized Antibiotics at the
American Thoracic Society International Meeting
1999
Roundtable Discussion Leader on Aerosolized Antibiotics in Cystic Fibrosis at the
1999 International North American Cystic Fibrosis Foundation Meeting
2000
Site Visit to Affiliate CF Program in Spokane, WA
2000
Chairperson, Committee on Early Interventions in Cystic Fibrosis, Northwest
Cystic Fibrosis Consortium, Epidemiologic Study in Cystic Fibrosis (Genentech)
2000
Invited to Cystic Fibrosis Foundation Williamsburg Conference
2000Member, Cystic Fibrosis Foundation (CFF) Clinical Research Committee for
National Review of Research Grants
2001
Invited Speaker at American Thoracic Conference, “Impact of Early Antibiotic
Treatment in Young Children with Cystic Fibrosis”
2001Member, CFF-TDN Committee to Establish Quality Control Standards for
Pulmonary Function Testing
4
Ronald L. Gibson, Jr., M.D., Ph.D.
2001
2002
20022002
20022003
Member, CFF-TDN Task Force for Re-Structuring of the Therapeutics
Development Network
Member, Nominating Committee for Pediatric Pulmonary Training Directors
Association Officers
Member, Steering Committee on Joint Project between the CFF and Proteome
Systems (Australia)
Invited Speaker at the 2002 European CF Conference in Genoa, Italy,
“Tobramycin Solution for Inhalation in Young Children with CF: Eradication of
Lower Airway Pseudomonas”
Member, Protocol Development Committee for the CF Therapeutics Development
Network
Invited Speaker, “Pseudomonas Summit”, Cystic Fibrosis Foundation, Bethesda
Special Local Responsibilities/Committees
1988University of Washington Pediatric Housestaff Selection-interviewer
1988-1990
University of Washington Pediatric Intern Selection Committee
1989
WAMI Visiting Professor, Sacred Heart Medical Center, Spokane, Washington
1989
WAMI Visiting Professor, Yakima Pediatric Associates, Yakima, Washington
1990Associate Director, Pediatric Pulmonary Center Training Grant (MCH #539167)
1990
WAMI Visiting Professor, Yakima Pediatric Associates, Yakima, Washington
1991-2001
Pharmacy and Therapeutics Committee, Children's Hospital & Medical Center,
Seattle, Washington
1991
Pediatric Grand Rounds at Children’s Hospital & Regional Medical Center:
Update on Bronchopulmonary Dysplasia
1991
WAMI Visiting Professor, Yakima Pediatric Associates, Yakima, Washington
1992Co-Director, Pediatric Pulmonary Fellowship Program, University of Washington
School of Medicine, Seattle, Washington
1992Director, Pediatric Pulmonology Weekly Journal Club, Children's Hospital &
Regional Medical Center, Seattle, Washington
1992
WAMI Visiting Professor, Yakima Pediatric Associates, Yakima, Washington
1993-5
PMD Representative to Virginia Mason, South, Children's Hospital & Medical
Center, Seattle, Washington
1993
WAMI Visiting Professor, Yakima Pediatric Associates, Yakima, Washington
1994
Chairman, Asthma Clinical Care Pathway, Children's Hospital & Medical Center,
Seattle, Washington
1994
WAMI Visiting Professor, Yakima Pediatric Associates, Yakima, Washington
1994-95
POD C Outpatient Clinics Workgroup, Committee Member, Children's Hospital &
Medical Center, Seattle, Washington
1995
Pediatric Grand Rounds at Children’s Hospital & Regional Medical Center:
Review of Asthma Clinical Pathway
1995
Speaker at Parent’s Day Educational Conference on Cystic Fibrosis
1995
WAMI Visiting Professor, Yakima Pediatric Associates, Yakima, Washington and
Toppenish Farm Workers Clinic/Providence Hospital, Toppenish, Washington
1996
Chairman, Asthma Clinical Care Pathway Revision I, Children’s Hospital &
Medical Center, Seattle, WA
1996
Member, Laboratory Space Committee for the Department of Pediatrics,
University of Washington School of Medicine, Seattle, WA
5
Ronald L. Gibson, Jr., M.D., Ph.D.
1996
1996-1998
19961996
1997
1999
1997
1998
1998
1998
1998
1998-
1998
19981999
1999
1999
1999
1999
2000
2000
2000
2001
2002
2002
2003
WAMI Visiting Professor, Yakima Pediatric Associates, Yakima, Washington and
Toppenish Farm Workers Clinic/Providence Hospital, Toppenish, Washington
Associate Director of the Cystic Fibrosis Center, Children’s Hospital & Medical
Center, Seattle, Washington
Member, Grand Rounds Steering Committee, Children’s Hospital & Medical
Center, Seattle, WA
Member, Cardiovascular Surgery Quality Assurance Committee, Children’s
Hospital & Medical Center, Seattle, WA
Asthma Managed Care Focus Group, Children’s Hospital and Regional Medical
Center, Seattle, WA
Chairperson, Asthma Clinical Pathway Revision II, Children’s Hospital & Regional
Medical Center, Seattle, WA
Member of Internal Review Committee for Child & Adolescent Psychiatry Training
Program, University of Washington/CHRMC, Seattle, WA
Speaker at Parent’s Day Educational Conference on Cystic Fibrosis
Team Member for Care Coordination Pilot with Asthma Patients, CHRMC,
Seattle, WA
Team Member for the Cystic Fibrosis Managed Care Readiness Project,
CHRMC, Seattle, WA
Acting Director of the Cystic Fibrosis Center, CHRMC, Seattle, WA
Center Director, Pediatric Program Director for the Cystic Fibrosis Center,
University of Washington, Children’s Hospital & Regional Medical Center, Seattle,
WA
Chairperson, Cystic Fibrosis Clinical Pathway Revision Committee, CHRMC,
Seattle, WA
Local Spokesperson for Great Strides Fundraiser for Cystic Fibrosis
Speaker at Parent’s Day Educational Conference on Cystic Fibrosis
Member, Asthma Clinical Pathway Revision Committee, CHRMC, Seattle, WA
CHRMC Quarterly Curbstone Consult: Chronic Cough (Editor, Dr. S. Dassel)
Chairperson, CHRMC Pharmacy & Therapeutics Subcommittee for Palivizumab
(Synagis) Guidelines
Speaker at 19th Annual F. Richard Dion Pediatric Update, Seattle, WA
Speaker at Parent’s Day Educational Conference on Cystic Fibrosis
WWAMI Visiting Professor, Peninsula Children’s Clinic, Port Angeles, WA
CHRMC Quarterly Curbstone Consult: Asthma Pathway (Editor: Dr. S. Dassel)
Speaker at Parent Day Educational Conference on Cystic Fibrosis
Site Visit to Affiliate CF Center, Anchorage, Alaska
Invited Speaker at Puget Sound Allergy & Asthma Society Meeting
Site Visit to Affiliate CF Center, Spokane, Washington
Research Funding
Name of Individual: Ronald L. Gibson, MD, PhD
Role: Co-Director of Pediatric Pulmonary Fellowship Training Program
ACTIVE
Project Number: 6T72-MC-00007
Dates of Project: 7/1/00-6/30/05
Principal Investigator: Greg Redding, MD
Percent Effort: 5%
Source: Maternal Child Health Bureau/HRSA
Direct Costs: $310,000
Title of Project: Pediatric Pulmonary Training Grant
6
Ronald L. Gibson, Jr., M.D., Ph.D.
Major goals of this project: To provide interdisciplinary clinical and leadership graduate training to health
care professionals focused on children with chronic pulmonary conditions.
Name of Individual: Ronald L. Gibson, MD, PhD
ACTIVE
(Renewable annually)
Project Number: C117-03
Dates of Current Project: 7/1/03-6/30/04
Principal Investigator: Ronald L. Gibson, MD, PhD
Percent Effort: 5%
Source: Cystic Fibrosis Foundation
Direct Costs: $222,114
Title of Project: Cystic Fibrosis Center Grant
Major goals this project: Funding for ongoing support of the Cystic Fibrosis Clinical Center.
Name of Individual: Ronald L. Gibson, MD, PhD
ACTIVE
Project Number: GIBSON98Y0
Dates of Entire Project: 4/1/98-10/31/03
Principal Investigator: Ronald L. Gibson, MD, PhD
Percent Effort: 12%
Source: Cystic Fibrosis Foundation
Current Direct Costs: $208,333
Title of Project: Therapeutic Development Center
Major goals of this project: Develop and conduct Phase I/II clinical trials in cystic fibrosis related research
as part of the Cystic Fibrosis Foundation's Therapeutic Development Network.
Name of Individual: Ronald L. Gibson, MD, PhD
Role: Co-Investigator
ACTIVE
Project Number: NIH R01 DK57755-04
Dates of Project: 7/01/00-4/30/04
Principal Investigator: Bonnie W. Ramsey, MD
Percent Effort: 30%
Source: NIH
Current Direct Costs: $615,337
Title of Project: Inhaled Tobramycin in Young Cystic Fibrosis Patients
Major goals of this project: The primary goal of this project is to investigate the efficacy of inhaled
Tobramycin in cystic fibrosis patients between 0 and 5 years of age.
Name of Individual: Ronald L. Gibson, MD, PhD
Role: Co-Investigator, Director of Clinical Core
ACTIVE
Project Number: R565
Dates of Project: 10/1/02-9/30/05
Principal Investigator: Samuel I. Miller, MD
Percent Effort: 5%
Source: Cystic Fibrosis Foundation
Direct Costs: $42,000
Title of Project: Molecular Biology of Cystic Fibrosis: Clinical Core
Major goals of this project: The primary goal of the RDP clinical core is to provide a national resource for
development of well-designed clinical investigations in patients with CF and to foster collaboration with
basic scientists to promote pilot studies by providing patient specimens or clinical data.
Name of Individual: Ronald L. Gibson, MD, PhD
Role: Principal Investigator
ACTIVE
Project Number: N/A
Dates of Project: 4/1/03-5/31/04
Principal Investigator: Ronald L. Gibson, MD, PhD
Percent Effort: 10%
Source: Salus Pharma, Inc.
Direct Costs: $7,569/pt
Title of Project: Safety and Tolerability Study of Ascending Single Doses of Aztreonam for Inhalation (AI)
in Patients with CF
Major goals of this project: The primary goal of this project is to evaluate the safety and tolerability of three
different doses of AI in patients with CF.
7
Ronald L. Gibson, Jr., M.D., Ph.D.
Name of Individual: Ronald L. Gibson, MD, PhD
Role: Co-Investigator
ACTIVE
Project Number:
Dates of Project: 11/1/00-10/31/03
Principal Investigator: Ronald L. Gibson, MD, PhD
Percent Effort: 0%
Source: Firland Foundation
Direct Costs: $20,000
Title of Project: A Randomized, Double-Blind, Placebo-Controlled Trial of Oral Corticosteroid Therapy in
Cystic Fibrosis Patients Hospitalized for Pulmonary Exacerbations
Major goals of this project: The primary goal of this project is to evaluate the safety and effectiveness of
the addition of oral prednisone to standard therapy in CF patients hospitalized for pulmonary exacerbation.
CURRENT CLINICAL STUDIES:
Sponsor: Cystic Fibrosis Foundation
Title of Study: Standard vs. Biofilm Susceptibility Testing in CF
Sponsor: University of California San Francisco/Cystic Fibrosis Foundation
Title of Study: Cystic Fibrosis Once Daily Aminoglycoside Clinical Trial (CFODACT)
Sponsor: Cystic Fibrosis Foundation
Title of Study: A Multi-Center Trial of Topical Aminoglycosides to Activate Cystic Fibrosis Genes in Cystic
Fibrosis Patients
Sponsor: Altus Biologics
Title of Study: A Phase I, Open-Label Safety and Tolerability Study of Oral TheraCLECTM_Total in
Subjects with Cystic Fibrosis
Sponsor: Children’s Hospital and Regional Medical Center
Title of Study: A Pilot Study of Sputum Induction as a Non-Invasive Means to Measure Serial Airway
Antibiotic Concentrations in Cystic Fibrosis
Sponsor: Cystic Fibrosis Foundation
Title of Study: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of INS37217
Inhalation Solution in Subjects with Mild to Moderate Cystic Fibrosis Lung Disease
Peer-Reviewed Publications
1.
2.
3.
4.
5.
Gibson, R, Leavitt, R, Kornfeld, S, and Schlesinger, S: Synthesis and infectivity of
vesicular stomatitis virus containing nonglycosylated G protein. Cell 13:671-679, 1978.
Gibson, R, Schlesinger, S, and Kornfeld, S: The nonglycosylated glycoprotein of
vesicular stomatitis virus is temperature sensitive and undergoes intracellular
aggregation at elevated temperatures. J. Biol. Chem. 254:3600-3607, 1979.
Li, E, Gibson, R, and Kornfeld, S: Structure of an unusual complex-type oligosaccharide
isolated from Chinese hamster cells. Arch. Biochem. Biophys. 199:393-399, 1980.
Gibson, R, Kornfeld, S, and Schlesinger, S: A role for oligosaccharides in glycoprotein
biosynthesis. TIBS 5:290-293, 1980.
Gibson, R, Kornfeld, S, and Schlesinger, S: The effect of oligosaccharide chains of
different sizes on the maturation and physical properties of the G protein of vesicular
stomatitis virus. J. Biol. Chem. 256:456-462, 1981.
8
Ronald L. Gibson, Jr., M.D., Ph.D.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
Gibson, RL, Truog, WE, and Redding, GJ: Hypoxic pulmonary vasoconstriction during
and following infusion of group B streptococcus in neonatal piglets: vascular pressureflow analysis. Am. Rev. Respir. Dis.137:774-778, 1988.
Gibson, RL, Truog, WE, and Redding, GJ: Thromboxane-associated pulmonary
hypertension during three types of gram-positive bacteremia in piglets. Pediatr. Res.,
23:553-556, 1988.
Truog, WE, Gibson, RL, Juul, SE, Henderson, WR, and Redding, GJ: Neonatal group B
streptococcal sepsis: Effects of late treatment with dazmegrel. Pediatr. Res., 23:352356, 1988.
Gibson, RL, Jackson, JC, Twiggs, GA, Redding, GJ, and Truog, WE: Bronchopulmonary
dysplasia: survival after prolonged mechanical ventilation. Am. J. Dis. Child., 142:721725, 1988.
Redding, GJ, Gibson, RL, Davis, CB, and Truog, WE: Effects of respiratory alkalosis on
thromboxane-induced pulmonary hypertension in piglets. Pediatr. Res., 24(5):558-562,
1988.
Gibson, RL, Redding, GJ, Truog, WE, Henderson, WR, and Rubens, CE: Isogenic
group B streptococci devoid of capsular polysaccharide or β-hemolysin: pulmonary
hemodynamic and gas exchange effects during bacteremia in piglets. Pediatr. Res.,
26(3):241-245, 1989.
Redding, GJ, Gibson, RL, Standaert TA, Truog, WE: Regional pulmonary blood flow in
piglets during group B streptococcal bacteremia. Am. Rev. Respir. Dis. 141:1209-1213,
1990.
Truog, WE, Gibson, RL, Henderson, WR, Redding, GJ: Tumor necrosis factor-induced
neonatal pulmonary hypertension: effects of dazmegrel pre-treatment. Pediatr. Res.
27(5):466-471, 1990.
Redding, GJ, Walund, L, Walund, D, Jones, JW, Stamey, DC, and Gibson, RL: Lung
function in children following empyema: influence of pleural drainage. Amer. J. Dis.
Child. 144:1337-1342, 1990.
Gibson, RL, Redding, GJ, Henderson, WR, Truog, WE: Group B streptococcus induces
tumor necrosis factor (TNF) in neonatal piglets: effect of the TNF inhibitor, pentoxifylline
on hemodynamics and gas exchange. Am. Rev. Respir. Dis. 143:598-604, 1991.
Ramsey, B, Wentz, K, Smith, A, Richardson, M, Williams-Warren, J, Hedges, D, Gibson,
R, Redding, GJ: Predictive value of oropharyngeal cultures for identifying lower airway
bacteria in cystic fibrosis. Am. Rev. Respir. Dis., 144:331-337, 1991.
Standaert, TA, Willham, BE, Mayock, DE, Watchko, JF, Gibson, RL, Woodrum, DE:
Respiratory mechanics of the piglet during the first month of life. Pediatr. Pulm. 11:294301, 1991.
Truog, WE, Gibson, RL, Henderson, WR, Redding, GJ, Standaert, TA: Effect of
pentoxifylline on cytokine and eicosanoid induced acute pulmonary hypertension in
piglets. Pediatric Res. 31(2):163-169, 1992.
Gibson, RL, Truog, WE, Henderson, WR, Redding, GJ: Group B streptococcal sepsis in
piglets: effect of combined pentoxifylline and indomethacin pretreatment. Pediatr. Res.
31(3):222-227, 1992.
Murphy, TD, Mayock, DE, Standaert, TA, Gibson, RL, Woodrum, DE: Group B
streptococcus has no effect on piglet diaphragmatic force generation. Am. Rev. Resp.
Dis. 145:471-475, 1992.
9
Ronald L. Gibson, Jr., M.D., Ph.D.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
Gibson, RL, Lee, MK, Soderland, C, Chi, EY, Rubens, CE: Group B streptococci invade
endothelial cells: type III capsular polysaccharide attenuates invasion. Infection &
Immunity, 61(2):478-485, 1993.
Murphy, TD, Gibson, RL, Standaert, TA, Mayock, DE, Woodrum, DE: Effect of group B
streptococcal sepsis on diaphragmatic function in young piglets. Pediatr. Res. 33(1):1014, 1993.
Berger, JI, Gibson, RL, Redding, GJ, Standaert, TA, Clarke, WR, Truog, WE: Effect of
inhaled nitric oxide during group B streptococcal sepsis in piglets. Amer. Rev. Respir.
Dis. 147:1080-1086, 1993.
Ramsey, BW, Astley, SJ, Aitken, MR, Burke, W, Colin, AA, Dorkin, HL, Eisenberg, JD,
Gibson, RL, et al.: Efficacy and safety of short term administration of aerosolized
recombinant human deoxyribonuclease in patients with cystic fibrosis (CF). Amer. Rev.
Respir. Dis. 148:145-151, 1993.
Ramsey, BW, Dorkin, HL, Eisenberg, JD, Gibson, RL, Harwood, IR, Kravitz, RM,
Schidlow, DV, Wilmott, RW, Astley, SJ, McBurnie, MA, Wentz, K, Smith, AL: The
efficacy of high dose tobramycin aerosol administration in patients with cystic fibrosis. N.
Engl. J. Med. 328(24):1740-1746, 1993.
Berger, JI, Gibson, RL, Clarke, WR, Standaert, TA, Redding, GJ, Henderson, WR,
Truog, WE: Effect of amrinone during group B streptococcus induced pulmonary
hypertension in piglets. Peds Pulmonol 16(5):303-310, 1993.
Gibson, RL, Davis, CB, Standaert, TA, Truog, WE, Redding, GJ: Lung vascular
responses and V
_ A/Q
_ matching after chronic hypoxia in neonatal piglets. J. Develop.
Physiol. 19(4):157-163, 1993.
Fuchs, HJ, Borowitz, DS, Christiansen, DH, et al. and the Pulmozyme Study Group (RL
Gibson, member): Effect of aerosolized recombinant human DNase on exacerbations of
respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N. Engl.
J. Med. 331:637-742, 1994.
Gibson, RL, Berger, JI, Redding, GJ, Standaert, TA, Mayock, DE, Truog, WE: Effect of
nitric oxide synthase inhibition during group B streptococcal sepsis in neonatal piglets.
Pediatr Res 36: 776-783, 1994.
Murphy, TD, Gibson, RL, Standaert, TA, Woodrum, DE: Diaphragmatic failure during
group B streptococcal sepsis in piglets: the role of thromboxane A 2. J Appl Physiol 78
(2): 491-498, 1995.
Gibson, RL, Soderland, C, Henderson, WR, Chi, EY, Rubens, CE: Group B streptococci
injure lung endothelium in vitro: increased invasion and eicosanoid production with
microvascular compared to pulmonary artery cells. Infect Immun 63:271-279, 1995.
Juul, SE, Kinsella MG, Truog WE, Gibson RL, Redding GJ. Lung hyaluronan decreases
during group B streptococcal pneumonia in neonatal piglets. Amer J Respir Crit Care
Med 153: 1567-70, 1996.
Zabner J, Ramsey BW, Meeker DP, Aitken ML, Balfour RP, Gibson RL, Launspach J,
Moscicki RA, Richards SM, Standaert TA, Williams-Warren J, Wadsworth SC, Smith AE,
Welsh MJ. Repeat administration of an adenovirus vector encoding CFTR to the nasal
epithelium of patients with cystic fibrosis. J Clin Invest 97 (6): 1504-11, 1996.
Nizet V, Gibson RL, Chi EY, Framson PE, Hulse M, Rubens CE. Group B streptococcal
β-hemolysin expression is associated with injury to lung epithelial cells. Infect Immun
64(9): 3818-3826, 1996.
10
Ronald L. Gibson, Jr., M.D., Ph.D.
35.
*36.
*37.
38.
*39.
*40.
41.
42.
43.
*44.
45.
*46.
47.
48.
Nizet V, Gibson RL, Rubens CE. The role of group B streptococci beta-hemolysin
expression in newborn lung injury. Adv Exp Med Biol 418:627-630, 1997.
Gibson RL, Nizet VF, Rubens CE. Group B streptococcal β-hemolysin promotes injury of
lung microvascular endothelial cells. Pediatric Research 45:626-634, 1999.
Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, Hiatt P, McCoy K,
Castile R, Smith AL, Ramsey BW. Longitudinal assessment of Pseudomonas aeruginosa
in infants with cystic fibrosis. Journal of Infectious Diseases 183: 444-52, 2001.
Noone PG, Hamblett N, Accurso F, Aitken M, Boyle M, Dovey M, Gibson R, Johnson C,
Kellerman D, Konstan M, Milgram L, Mundahl J, Rodman D, Williams-Warren J, Wilmott
R, Zeitlin P, Ramsey R. Safety of aerosolized INS 365 in patients with mild to moderate
cystic fibrosis: results of a phase I multi-center trial. Pediatric Pulmonology 32: 122-8,
2001.
Rosenfeld M, Gibson RL, McNamara S, Emerson J, McCoy K, Schell R, Borowitz D,
Konstan M, Retsch-Bogart G, Wilmott R, Burns JL, Ramsey B. Serum and lower
respiratory tract drug concentrations produced by tobramycin for inhalation in young
children with cystic fibrosis. Journal of Pediatrics 139 (4): 572-7, 2001.
Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castile R, Hiatt P, McCoy
K, Wilson CB, Inglis A, Martin TR, Ramsey, BW. Early pulmonary infection,
inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatric Pulmonology
32: 356-366, 2001.
Aitken ML, Moss RB, Waltz DA, Dovey ME, Tonelli MR, Gibson RL, Ramsey BW, Carter
BJ, Reynolds TC. A Phase I study of aerosolized administration of tgAAVCF to CF
subjects with mild lung disease. Human Gene Therapy 12:1907-1916, 2001.
Brogan TV, Finn LS, Pyskaty Jr DJ, Redding GJ, Ricker D, Ingliss A, Gibson RL.
Plastic bronchitis in children: a case series and review of the medical literature.
Pediatric Pulmonology 34: 482-487, 2002.
Conway K, Gibson RL, Perkins J, Cunningham ML. Pulmonary agenesis: expansion of
the VCFS phenotype. American Journal of Medical Genetics 113: 89-92, 2002.
Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas
aeruginosa and other predictors of mortality and morbidity among young children with
cystic fibrosis. Pediatric Pulmonology 34:91-100, 2002.
Aitken ML, Tonelli MR, Pier MV, Burns JL, Emerson JC, Goss CH, McNamara SC,
Gibson RL. Analysis of sequential aliquots of hypertonic saline induced sputum from
stable patients with cystic fibrosis. Chest 123:792-799, 2003.
Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N,
Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz
D, Wilmott R, Zeitlin PL, Ramsey B, and the CFF Therapeutics Development Network
Study Group. A significant microbiologic effect of inhaled tobramycin in young children
with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 167:841849, 2003.
Cunningham ML, Perry RJ, Eby PR, Gibson RL, Opheim KE, Manning SC. Primary
pulmonary dysgenesis in velocardiofacial syndrome: a second patient. American Journal
of Medical Genetics 121A:177-9, 2003.
Ordoñez CL, Henig NR, Gibson RL, Hamblett N, Accurso FJ, Burns JL, Chmiel JF, Daines C,
McNamara S, Retsch-Bogart GZ, Zeitlin PL, Aitken ML. Validation of sputum induction as
an outcome measure for lower airway sampling in subjects with cystic fibrosis.
American Journal of Respiratory and Critical Care Medicine, in press, 2003.
11
Ronald L. Gibson, Jr., M.D., Ph.D.
*49.
50.
Gibson RL, Burns JL, Ramsey BW. State of the Art: Pathophysiology and management
of pulmonary infections in cystic fibrosis. American Journal of Respiratory and Critical
Care Medicine 168: 918-951, 2003.
Rosenfeld M, Ramsey BW, Gibson RL. Pseudomonas aeruginosa acquisition in young
patients with cystic fibrosis: pathophysiology, diagnosis, and management. Current
Opinion in Pulmonary Medicine 9(6):492-7, 2003.
Book Reviews
1.
Gibson, RL. Review of Kendig’s Disorders of the Respiratory Tract in Children, Sixth
Edition. Chernick, V, Boat, T (editors). W.B. Saunders, Philadelphia, PA.
Doody Review Service (http://www.doody.com). 1997.
2.
Gibson, RL. Review of Pediatric Respiratory Medicine. Taussig, L and Landau, L
(editors). Mosby, St. Louis, MO. Doody Review Service (http://www.doody.com). 1999.
Abstracts
1.
Zitomer, RS, Gibson, RL, and Hall, BD: In vitro translation of cytochrome mRNA.
Presented. Cold Spring Harbor Symposium: The Molecular Biology of Yeast, page 28,
1975.
2.
Gibson, RL, Schlesinger, S, and Kornfeld, S: The nonglycosylated glycoprotein of VSV
is temperature-sensitive and undergoes aggregation at elevated temperatures.
Presented 8th Annual ICN-UCLA Symposia on Molecular and Cellular Biology. Journal
of Supermolecular Structure, supplement 3, page 96, 1979.
3.
Redding, GJ, Gibson, R, Twiggs, G, Standaert, TA, and Truog, WE: Reduced pulmonary
blood flow improves gas exchange in newborn piglets. Presented. American Thoracic
Society, 1986. Am. Rev. Resp. Dis. 133(4), Part 2:A151, 1986.
4.
Gibson, RL and Redding, GJ: Hypoxic pulmonary vasoconstriction persists following
infusion of Group B streptococcus in neonatal piglets. J. Critical Care 1(1):32, 1987.
5.
Gibson, RL, Truog, WE, and Redding, GJ: Nonspecific thromboxane-mediated
pulmonary hypertension in neonatal gram-positive sepsis. Am. Rev. Resp. Dis., 135(4),
Part 2:A124, 1987.
6.
Redding, GJ, Gibson, RL, Standaert, TA, and Truog, WE: Lobar inflammation produced
by zymosan-activated serum increases shunt fraction in piglets with lobar atelectasis.
Am. Rev. Resp. Dis., 135(4), Part 2:A124, 1987.
7.
Redding, GJ, Gibson, RL, and Truog, WE: Group B streptococcus (GBS) induced
pulmonary hypertension does not alter shunt produced by atelectasis in piglets. Am.
Rev. Resp. Dis., 135(4), Part 2:123, 1987.
8.
Truog, WE, Gibson, RL, Juul, SE, Henderson, W, and Redding, GJ: Neonatal group B
streptococcal (GBS) sepsis: Therapeutic implications of thromboxane synthetase
(TxA2) inhibition. Pediatr. Res. 21(4), Part 2:468A, 1987.
9.
Redding, GJ, Gibson, RL, Standaert, TA, and Truog, WE: Effects of hyperventilation
upon pulmonary vasoconstriction induced by a thromboxane mimetic in piglets.
Presented. American Thoracic Society, 1988. Am. Rev. Respir. Dis. 137(4) Part 2:105,
1988.
10.
Standaert, TA, Willham, BE, Mayock, DE, Gibson, RL, and Woodrum, DE: Lung volume
and pulmonary compliance of the piglet during the first month of life. Presented.
American Thoracic Society, 1988. Am. Rev. Respir. Dis. 137(4) Part 2:382, 1988.
12
Ronald L. Gibson, Jr., M.D., Ph.D.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
Redding, GJ, Davis, CB, Juul, SE, Gibson, RL, Truog, WE: Effects of angiotensin on
pulmonary hemodynamics and gas exchange in piglets. Presented. American Thoracic
Society. 1989. Am. Rev. Respir. Dis. 139(4), Part 2:A440, 1989.
Davis, CB, Gibson, RL, Truog, WE, Redding, GJ: Chronic hypoxia induced changes in
the pulmonary hemodynamics of neonatal swine: pressure flow analysis. Presented.
American Thoracic Society, 1989. Am. Rev. Respir. Dis. 139(4), Part 2:A437, 1989.
Gibson, RL, Redding, GJ, Truog, WE, Rubens, CE: A type III group B streptococcus
(GBS) mutant devoid of capsular polysaccharide causes pulmonary hypertension and
hypoxemia in piglets. Presented. American Thoracic Society, 1989. Am. Rev. Respir.
Dis. 139(4), Part 2:A439, 1989.
Gibson, RL, Redding, GJ, Truog, WE: Tumor necrosis factor (TNF): potential mediator
of neonatal group B streptococcal (GBS) sepsis. Presented. American Thoracic
Society, 1989. Am. Rev. Respir. Dis. 139(4), Part 2:A439, 1989.
Truog, WE, Gibson, RL, Henderson, WR, Redding, GJ: Tumor necrosis factor-induced
neonatal pulmonary hypertension: effects of dazmegrel pretreatment. Presented.
Society for Pediatric Research, 1989. Pediatr. Res. 25(4), Part 2:329A, 1989.
Redding, GJ, Gibson, RL, Davis, CB, Standaert, TA, Truog, WE: Reduced cardiac
output does not alter distribution of pulmonary blood flow to atelectatic lung regions in
piglets. Presented. 1990 World Conference on Lung Health -- American Thoracic
Society. Am. Rev. Respir. Dis. 141(4), Part 2:A740, 1990.
Murphy, TD, Standaert, TA, Gibson, RL, Mayock, DE, Woodrum, DE: Group B
streptococcal (GBS) sepsis impairs diaphragmatic function in the piglet. Presented.
1990 World Conference on Lung Health -- American Thoracic Society. Am. Rev. Respir.
Dis. 141(4), Part 2:A549, 1990.
Gibson, RL, Redding, GJ, Henderson, WR, Truog, WE: Combined pentoxifylline and
indomethacin pretreatment attenuates early and late features of group B streptococcal
sepsis in piglets. Presented. 1990 World Conference on Lung Health -- American
Thoracic Society. Am. Rev. Respir. Dis. 141(4), Part 2:A688, 1990.
Davis, CB, Gibson, RL, Redding, GJ, Standaert, TA, Truog, WE: Effects of acute and
chronic alveolar hypoxia on gas exchange in neonatal swine. Presented. 1990 World
Conference on Lung Health -- American Thoracic Society. Am. Rev. Respir. Dis. 141(4),
Part 2:A852, 1990.
Gibson, RL, Redding, GJ, Truog, WE, Rubens, CE: Neonatal group B streptococcal
(GBS) sepsis: the role of GBS capsular polysaccharide in tumor necrosis factor (TNF)
production in piglets. Presented. Federation of American Societies for Experimental
Biology, 1990. FASEB Journal 4:A355, 1990.
Truog, WE, Redding, GJ, Standaert, TA, Gibson, RL: Effect of pentoxifylline on tumor
necrosis factor-induced pulmonary hypertension in piglets. Presented. Federation of
American Societies for Experimental Biology, 1990. FASEB Journal 4:A573, 1990.
Redding, GJ, Gibson, RL, Standaert, TA, Truog, WE: Atelectasis does not inhibit
pulmonary inflammation due to experimental streptococcal pneumonia. Am. Rev.
Respir. Dis. 143(4), Part 2:A787, 1991.
Gibson, RL, Truog, WE, Standaert, TA, Redding, GJ, Rubens, CE: Endothelial cell
invasion by group B streptococci. Presented. Society for Pediatric Research, 1991.
Pediatr. Res. 29(4), Part 2:A281, 1991.
Murphy, TD, Standaert, TA, Gibson, RL, Mayock, DE, Woodrum, DE: Group B
streptococcal shock impairs diaphragmatic contractility in the piglet. Am. Rev. Respir.
Dis. 143(4), Part 2:A560, 1991.
13
Ronald L. Gibson, Jr., M.D., Ph.D.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
Berger, JI, Clarke, WR, Gibson, RL, Standaert, TA, Redding, GJ, Truog, WE: Effects of
amrinone on pulmonary vascular resistance and V/Q matching during group B
streptococcal sepsis in piglets. Presented. Society for Pediatric Research, 1991.
Pediatr. Res. 29(4), Part 2:A308, 1991.
Murphy, TD, Gibson, RL, Standaert, TA, Mayock, DE, Woodrum, DE: The thromboxane
A2 mimetric, U46619, decreases piglet diaphragmatic contractility. Presented. American
Thoracic Society, 1992. Am. Rev. Respir. Dis. 145(4) Part 2:A671, 1992.
Berger, JI, Gibson, RL, Standaert, TA, Redding, GJ, Clarke, WR, Truog, WE: Effect of
inhaled nitric oxide on pulmonary vascular resistance (PVR) during group B streptococcal
(GBS) sepsis in piglets. Presented. The Society for Pediatric Research, 1992. Pediatr.
Res. 31(4), Part 2:301A, 1992.
Berger, JI, Gibson, RL, Redding, GJ, Standaert, TA, Truog, WE: Effect of Nω-Nitro-LArginine Methyl Ester (L-NAME) on pulmonary hemodynamics during group B
streptococcal (GBS) sepsis in piglets. Presented. Society for Pediatric Research, 1993.
Pediatr. Res. 33(4):317A, 1993.
Gibson, RL, Soderland, C, Henderson, WR, Rubens, CE: Group B streptococci (GBS)
invade lung endothelium in vitro: increased invasion and eicosanoid release from
microvascular compared to pulmonary artery cells. Presented. American Thoracic
Society, 1993. Amer. Rev. Respir. Dis. 147(4):A132, 1993.
Gibson, RL, Soderland, C, Rubens, CE: Specific transposon mutants of group B
streptococcus (GBS) cause reduced lung microvascular endothelial cell injury in vitro.
Am. J. Resp. Crit Care Med. 149:A294, 1994.
Nizet, V, Gibson, RL, Chi EY, Rubens CE. Expression of group B streptococcal
hemolysin is associated with alveolar epithelial cell injury. Presented at the American
Society of Microbiology, 1995.
Gibson, RL, Nizet, V, Rubens CE. Group B streptococcal β-hemolysin contributes to
GBS-induced lung microvascular endothelial cell injury in vitro. Presented at the Society
for Pediatric Research, 1995. Pediatr Res 37 (4): 291A, 1995.
Nizet, V, Gibson, RL , Framson, PE, Chi, EY, Rubens CE. Group B streptococcal
hemolysin expression is correlated with epithelial cell injury. Presented at the Society for
Pediatric Research 1995. Pediatr Res 37 (4): 296A, 1995.
Nizet, V, Gibson, RL, Rubens, CE. Group B β-hemolysin expression and injury of
newborn lung. Presented at the Society for Pediatric Research May 1996 (abstract
15410).
Nizet, V, Gibson, RL, Rubens, CE. The role of GBS β-hemolysin expression in newborn
lung injury. Presented at the XIIIth International Lancefield Society Meeting, Paris,
France, Abstact # P109, 1996.
Ramsey, B., McNamara,S, Gibson, R, Emerson, J, Rosenfeld, M, Hiatt, P, McConnell, R,
McKoy, K, Lawrence C, Olson, P. P. aeruginosa colonization in young children with
cystic fibrosis. Pediatr Pulmonol, Supplement 17: page 320 (abstract #415), 1998.
Rosenfeld, M, Borowitz, D, Emerson, J, Gibson, R. Ingham, L, McCoy, K, McNamara, S.
Montgomery, B, Ramsey, B, Vicini ,P, Wilmott, B. Safety and serum pharmacokinetics of
inhaled tobramycin in very young CF patients. Presented at the 1999 North American
Cystic Fibrosis Meeting. Pediatr Pulmonol, supplement 19, page 262 (abstract #346),
1999.
Lewis, TC, Rosenfeld M, Gibson, RL, Ramsey, BW. Urban/Rural differences in
specialty health care utilization and health outcomes in cystic fibrosis. Presented at the
14
Ronald L. Gibson, Jr., M.D., Ph.D.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
1999 North American Cystic Fibrosis Meeting. Pediatr Pulmonol, Supplement 19, page
337 (abstract #600), 1999.
Moss, R, Kylstra, J, Gibson, RL. Who benefits more? An analysis of FEV1 and weight in
adolescent CF patients using inhaled tobramycin. . Presented at the 1999 North
American Cystic Fibrosis Meeting. Pediatr Pulmonol, Supplement 19, page 243 (abstract
#279), 1999.
Noone, PG, Accurso FJ, Aitken M, Dovey M, Gibson, RL, Konstan M, Rodman, DM,
Wilmott R, Zeitlin P, Gorden J, Shaffer C. Safety of aerosolized INS365 in patients with
mild to moderate CF: results of a multi-center therapeutic development network study.
Pediatr Pulmonol, Supplement 19, page 244 (abstract # 283), 1999.
Aitken, ML, Moss, RB, Waltz, DA, Dovey, ME, Tonelli, MR, Gibson, RL, Ramsey, BW,
Carter, BJ, Reynolds, TC. A Phase I study of aerosolized administration of tgAAVCF to
CF patients with mild lung disease. Pediatr Pulmonol, Supplement 20, page 236,
abstract # 226, 2000.
Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castille R, Hiatt P, McCoy
K, Wilson CB, Smith AL, Ramsey BW. Early course of pulmonary infection,
inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol,
supplement 20, S5.4 pages 112-114, 2000.
Aitken ML, Tonelli MR, Pier MV, Burns JL, Emerson JC, Goss CH, McNamara SC,
Gibson RL. Analysis of sequential aliquots of hypertonic saline induced sputum from
stable patients with cystic fibrosis. Pediatr Pulmonol., Supplement 22, abstract # 381,
page 302, 2001.
Gibson, RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N,
Accurso F, Dovey M, Hiatt P, Moss R, Konstan M, Retsch-Bogart G, Waltz D, Wilmott R,
Wagener J, Zeitlin P, Ramsey B. A randomized controlled trial of inhaled tobramycin in
young children with cystic fibrosis: eradication of Pseudomonas from the lower airway.
Presented at the North American CF Conference in October 2002. Pediatr Pulmonol.,
Supplement 24, abstract #356, page 300, 2002.
Ordonez C, Gibson RL, Emerson J, McNamara S, Accurso F, Burns JL, Zeitlin P, Daines
C, Retsch-Bogart G, Chmiel J, Henig N, Aitken M. Validation of sputum induction as an
outcome measure for lower airway sampling in patients with cystic fibrosis. Presented at
the North American CF Conference in October 2002. Pediatr Pulmonol., Supplement 24,
abstract # 354, page 299, 2002.
Cassidy J, Gibson RL, Moskowitz S. Clinical pathway for cystic fibrosis pulmonary
exacerbation. Pediatr Pulmonol., Supplement 24, abstract # 510, page 355, 2002.
Moss R, Wagener J, Daines C, Hale K, Ahrens R, Gibson R, Retsch-Bogart G, Nasr S,
Noth I, Waltz D, Zeitlin P, Ramsey B, Hamblett N, Starko K. Randomized, double-blind,
placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients
with mild-moderate cystic fibrosis lung disease. Am J Resp Crit Care Med 2003;
167:A923.
Rosenfeld M, Emerson J, McNamara S, Castile R, McCoy K, Hiatt P, Burns JL, Gibson
RL, Ramsey BW. Longitudinal follow-up of Pseudomonas aeruginosa infection in young
children with cystic fibrosis. Am J Resp Crit Care Med 2003; 167:A164
Hoffman LR, Emerson JE, Gibson RL, Redding GJ. Frequency of return to best PFT
baseline after CF cleanout: a pilot quality improvement project. Am J Respir Crit Care
Med 2003;167:A923.
15
Ronald L. Gibson, Jr., M.D., Ph.D.
50.
51.
52.
53.
54.
55.
56.
Moskowitz SM, Foster J, Emerson J, McNamara S, Gibson RL, Burns JL. Discordance of
conventional and biofilm antibiotic susceptibilities of Pseudomonas aeruginosa isolated
from cystic fibrosis airways. Am J Resp Crit Care Med 2003; 167:A322.
Clancy JP, Eubanks VL, Bebok Z, Franks K, Zeitlin P, Brass L, Aitken M, Gibson R,
Gordon M, Davies Z, Sorscer EJ, Bedwell DM. A randomized double-blind trial of topical
gentamicin and tobramycin to improve CFTR function in CF patients with and without
premature stop mutations. Pediatr Pulmonol, Supplement 25, abstract # 193, 2003.
Sagel S, Emerson J, Rosenfeld M, McNamara S, Caron H, Ramsey B, Wagener J,
Gibson R. Association of upper versus lower airway Pseudomonas aeruginosa infection
with endobronchial inflammation and clinical status in young children with CF. Pediatr
Pulmonol, supplement 25, abstract # 375, 2003.
Rosenfeld M, Caron H, Emerson J, Hamblett H, Burns JL, Gibson R, McNamara S, Hiatt
P, McCoy K, Castile R, Ramsey B. What effect do anti-pseudomonal antibiotics have on
serial upper airway cultures in infants with CF? Pediatr Pulmonol, supplement 25,
abstract # 374, 2003.
Waltz DA, Gibson R, McNamara S, Campbell J, Hamblett N, Ramsey B. Safety and yield
of clinical trial bronchoalveolar lavage procedures in young cystic fibrosis patients.
Pediatr Pulmonol, supplement 25, abstract # 393, 2003.
Gibson RL, Emerson J, McNamara S et al. Duration of the anti-pseudomonal treatment
effect of inhaled tobramycin in young children with cystic fibrosis. Pediatr Pulmonol,
supplement 25, abstract # 323, 2003.
Moskowitz SM, Foster J, Emerson J, Gibson RL, McNamara S, Burns JL. Development
of a numerical algorithm to select antibiotic regimens based on biofilm susceptibilities of
CF P. aeruginosa isolates. Pediatr Pulmonol, supplement 25, abstract # 335, 2003.
16